Overall survival results from MONALEESA-2: Endocrine therapy and ribociclib in HR positive and H...

MONALEESA-3 OS results: fulvestrant/ribociclib in postmenopausal HR+/HER2- advanced breast cancerПодробнее

GS2-01: "Overall survival subgroup analysis by metastatic site from the phase3 MONALEESA-2..."Подробнее

Ribociclib and endocrine therapy improves survival for pre-menopausal women with advanced breast...Подробнее

CDK4/6 inhibitor ribociclib plus fulvestrant improves overall survival in postmenopausal HR-posi...Подробнее

Ribociclib plus endocrine therapy improves survival in premenopausal patients with metastatic br...Подробнее

Final overall survival analysis of MONARCH 1Подробнее

MONARCH 2: Overall survival results from abermaciclib plus fulvestrant in HR+ HER2- advanced bre...Подробнее

Overall survival results from MONALEESA-3 study on ribociclib plus fulvestrant in advanced breas...Подробнее

MONALEESA-2: improved OS seen in HR+ advanced breast cancer treated with ribociclib + letrozoleПодробнее

HR–positive advanced breast cancer: Ribociclib improved PFS for pre and perimenopausal womenПодробнее

MONALEESA-7: Results from phase III trial looking at ribociclib as an addition to endocrine ther...Подробнее

Frontline endocrine therapies and ribociclib in early stage HR+ HER2- breast cancerПодробнее

Researcher comment: Ribociclib efficacy for visceral metastases | Denise YardleyПодробнее

Adding ribociclib to endocrine therapy shows an improvement in invasive DFS in HR+/HER2 BC patientsПодробнее

Ribociclib plus endocrine therapy boosts survival of HR+/HER2- breast cancerПодробнее

FDA Approval of Ribociclib for Metastatic Breast CancerПодробнее

Overall survival (OS) results of the Phase III MONALEESA-3 trialПодробнее

Dr. Hortobagyi on MONALEESA-2 Trial Results in Breast CancerПодробнее

DETECT V: second interim analysis of chemotherapy-free strategies in HER2-, HR+ mBCПодробнее